Meanwhile, aromatase inhibitors, representing an effective endocrine treatment for hormone receptor positive breast cancer patients, were suspected to be less effective in suppression of estrogen levels enough to prevent recurrence in obese women regardless of menopausal status [70, 71]. The gene discussed is CYP19A1; the disease is breast cancer.